knowledge -WSS

knowledge

author：fashion 2025-09-28 23:11:03 - browse：44962

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Sage hopes for a blockbuster in antidepressant now before FDA

entertainment

WSS

30 years of 'Listening to Prozac'

The high personal cost of affirmative action for Black doctors

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Fetal surgery at risk from Dobbs and new abortion restrictions

Sage hopes for a blockbuster in antidepressant now before FDA

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

In Memoriam: Notable people who died in 2023

What to do when lifesaving products contribute to climate change

BioMarin wins approval for gene therapy to treat hemophilia A

Mayo Clinic plans $5B tech

Tori Bowie and the unacceptable rates of Black maternal death

Physician groups backed by private equity giant lobby on mergers

Drug repurposing or repositioning? The language matters

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Trump demands the U.S. pay no more for drugs than other countries … again

Organ aging and disease risk measured by new blood test

focus

New safety details link Apellis eye drug to rare cases of blindness

Rep. Raul Ruiz on the physician shortage and more

Sage hopes for a blockbuster in antidepressant now before FDA

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Diagnostic tests are hitting their mathematical limits

focus

entertainment

explore

entertainment